Tumor suppressive role of miR-569 in lung cancer

microRNAs (miRs) are targets for genomic aberrations and emerging treatments against cancer. It has been demonstrated that targeting miR-569 may potentially benefit patients with ovarian or breast cancer. However, the exact roles of miR-569 remain unclear in human lung cancer cells. Using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR), it was demonstrated that miR-569 expression was consistently decreased in lung cancer cells. As well as cell proliferation and migration inhibition, apoptosis and cell arrest at the G1 phase were induced following reversion of miR-569 expression in lung cancer cells. The present study demonstrated that miR-569 was able to downregulate FOS and high mobility group A2 mRNA and protein expression using RT-qPCR and western blot analysis. The observed role of miRNA-569 in lung cancer cells in the present study suggested that it may be a novel and promising therapeutic target, and a novel biomarker for detecting lung cancer.

[1]  L. Resar,et al.  HMGA 2 Participates in Transformation in Human Lung Cancer , 2008 .

[2]  D. Cleveland,et al.  Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis , 2009, Nature Reviews Molecular Cell Biology.

[3]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[4]  Sun-Mi Park,et al.  Let-7 Prevents Early Cancer Progression by Suppressing Expression of the Embryonic Gene HMGA2 , 2007, Cell cycle.

[5]  M. Volm,et al.  Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[6]  Thomas Weigel,et al.  HMGA2 overexpression in non‐small cell lung cancer , 2007, Molecular carcinogenesis.

[7]  B. Schroen,et al.  MicroRNA Involvement in Immune Activation During Heart Failure , 2011, Cardiovascular Drugs and Therapy.

[8]  L. Resar,et al.  HMGA2 Participates in Transformation in Human Lung Cancer , 2008, Molecular Cancer Research.

[9]  T. Hunter,et al.  The c-fos protein interacts with c-Jun AP-1 to stimulate transcription of AP-1 responsive genes , 1988, Cell.

[10]  Y. Jeon,et al.  High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Jian-Jun Wei,et al.  HMGA2 and high-grade serous ovarian carcinoma , 2013, Journal of Molecular Medicine.

[12]  Derek Grose,et al.  The impact of comorbidity upon determinants of outcome in patients with lung cancer. , 2015, Lung cancer.

[13]  H. Sasaki,et al.  PIK3CA gene amplification in Japanese non-small cell lung cancer. , 2007, Lung cancer.

[14]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[15]  G. Mills,et al.  Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. , 2014, Cancer cell.

[16]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[17]  Jia Yu,et al.  MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. , 2013, Die Pharmazie.

[18]  P. Massion,et al.  Role of chromosome 3q amplification in lung cancer. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  T. Mitsudomi,et al.  fos oncogene transfer to a transformed rat fibroblast cell line enhances spontaneous lung metastasis in rat. , 1986, Japanese journal of cancer research : Gann.

[20]  G. Barreto,et al.  Epigenetics in lung cancer diagnosis and therapy , 2015, Cancer and Metastasis Reviews.

[21]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[22]  Karin Milde-Langosch,et al.  The Fos family of transcription factors and their role in tumourigenesis. , 2005, European journal of cancer.

[23]  Integrated analyses of copy number variations and gene differential expression in lung squamous-cell carcinoma , 2015, Biological Research.

[24]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[25]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[26]  A. Gartel,et al.  miRNAs: Little known mediators of oncogenesis. , 2008, Seminars in cancer biology.

[27]  Timothy Solberg,et al.  Particle Therapy for Non-Small Cell Lung Tumors: Where Do We Stand? A Systematic Review of the Literature , 2014, Front. Oncol..

[28]  R. D. De Mello,et al.  MicroRNAs in lung cancer , 2017, Oncotarget.

[29]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[30]  Yong Song,et al.  [Expression and its clinical significance of HMGA2 in the patients with non-small cell lung cancer.]. , 2008, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[31]  R. Garzon,et al.  Potential of microRNAs for cancer diagnostics, prognostication and therapy , 2012, Current opinion in oncology.

[32]  Jie Fan,et al.  Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer , 2016, Cancer biology & therapy.

[33]  Thomas Tuschl,et al.  miRNAs in human cancer , 2011, The Journal of pathology.